{"nctId":"NCT00838435","briefTitle":"Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU","startDateStruct":{"date":"2009-02"},"conditions":["Phenylketonuria"],"count":95,"armGroups":[{"label":"sapropterin dihydrochloride","type":"EXPERIMENTAL","interventionNames":["Drug: sapropterin dihydrochloride"]}],"interventions":[{"name":"sapropterin dihydrochloride","otherNames":["Kuvan","Phenoptin","BH4","6R BH4"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Established diagnosis of PKU with hyperphenylalaninemia (HPA) documented in the medical record by at least 2 blood Phe concentrations greater than or equal to 360 micromole/L (6 mg/dL) taken at least 3 days apart\n* Documented blood Phe control (defined by the standard used at each treatment center) prior to study enrollment, if applicable (eg, the subject is old enough for these data to be collected); blood Phe concentrations for subjects \\< 6 months old at Screening must be considered controlled and stable by the Investigator\n* Willing to adhere to a prescribed Phe restricted diet in order to maintain blood Phe concentrations within the recommended ranges established at the subject's study site\n* Age 0 to 6 years old, inclusive, at Screening\n* Parent(s) or guardian(s) willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures\n* Parent(s) or guardian(s) willing and able to comply with all study procedures\n* Female subjects of childbearing potential (as determined by the investigator) and sexually mature male subjects willing to use a medically accepted method of contraception throughout the study. Female subjects of childbearing potential willing to undergo periodic pregnancy tests during the course of the study\n\nExclusion Criteria:\n\n* Established diagnosis of primary tetrahydrobiopterin (BH4) deficiency\n* Known hypersensitivity to Kuvan or its excipients\n* History of organ transplantation\n* Perceived to be unreliable or unavailable for study participation or to have parents or legal guardians who are perceived to be unreliable or unavailable\n* Use of methotrexate or other medications that inhibit folate metabolism\n* Serious neuropsychiatric illness (eg, major depression) not currently under medical control\n* Use of Kuvan or any investigational agent within 30 days prior to Screening, or known requirement for any investigational agent prior to completion of all scheduled study assessments\n* Concurrent disease or condition that would interfere with study participation or safety (eg, seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin dependent diabetes)\n* Any condition that, in the view of the Principal Investigator (PI), renders the subject at high risk for failure to comply with treatment or to complete the study\n* Use of phosphodiesterase type 5 (PDE5) inhibitor.","healthyVolunteers":false,"sex":"ALL","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Full-Scale Intelligence Quotient (FSIQ) Score","description":"Full Scale Intelligence Quotient (FSIQ) is a score derived through administration of selected subtests from age appropriate Wechsler Intelligence assessments. Weschler Preschool and Primary Scale of Intelligence (WPPSI)-III is used for children \\>30 months and â‰¤6 years; and Weschler Intelligence Scale for Children (WISC)-IV is used for children \\>6 years old. The outcome variable will be the FSIQ score from WPPSI-III and/or WISC-IV tests.\n\nFSIQ results can range from 40 being the lowest and 160 being the highest. Higher scores are associated with higher intelligence quotient.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101.06","spread":"14.039"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.64","spread":"13.202"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.69","spread":"11.697"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.78","spread":"12.759"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.25","spread":"13.242"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.76","spread":"14.280"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.57","spread":"11.012"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.22","spread":"12.236"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events (AEs)","description":"Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, and that does not necessarily have a causal relationship with this treatment.\n\nDrug Related Adverse all noxious and unintended responses to a medical product related to any dose. This means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility, ie, the relationship cannot be ruled out.\n\nA serious adverse event (SAE) is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Growth Measurements - Height Z-Scores","description":"Z-scores of Height determined using World Health Organization(WHO) growth charts for children \\<24 months and Centers for Disease Control and Prevention(CDC) clinical growth charts for children 24 months and older.\n\nA height z-score is a standardized height measure after considering important factors like age and gender, in which higher z-scores are associated with taller children. Z-scores (or standard deviation scores) describe how far a measurement is from the median (mean). A z-score of 0 is the same as a 50th percentile; a positive value is a factor of standard deviation (SD) unit above the 50%; and a negative value is a factor of SD unit below 50%.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Growth Measurements - Weight Z-Scores","description":"Z-scores of Weight determined using World Health Organization(WHO) growth charts for children \\<24 months and Centers for Disease Control and Prevention(CDC) clinical growth charts for children 24 months or older.\n\nA weight z-score is a standardized weight measure after considering important factors like age and gender, in which higher z-scores are associated with heavier children. Z-scores (or standard deviation scores) describe how far a measurement is from the median (mean). A z-score of 0 is the same as a 50th percentile; a positive value is a factor of SD unit above the 50%; and a negative value is a factor of SD unit below 50%.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Growth Measurements - Head Circumference Z-Scores","description":"Z-scores of Head Circumference determined using World Health Organization(WHO) growth charts for children \\<24 months and Centers for Disease Control and Prevention(CDC) clinical growth charts for children 24 months and older.\n\nA head circumference z-score is a standardized head circumference measure after considering important factors like age and gender, in which higher z-scores are associated with children with larger heads. Z-scores (or standard deviation scores) describe how far a measurement is from the median (mean). A z-score of 0 is the same as a 50th percentile; a positive value is a factor of SD unit above the 50%; and a negative value is a factor of SD unit below 50%.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bayley-III Scores - Neurocognitive Testing Results","description":"The Bayley-III is a tool for assessing all facets of development in infants within an age range of 12 to 30 months, with normative data available for infants as young as 16 days. Composite scores are derived for cognitive, language, and motor development and scaled to a metric, with a range of 40 to 160. Higher scores are a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.31","spread":"9.081"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.68","spread":"10.943"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":"13.157"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"20.170"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"23.962"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.73","spread":"12.914"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":"10.966"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":"14.469"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.82","spread":"22.903"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.00","spread":"18.407"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.96","spread":"11.837"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"10.952"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":"12.297"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"19.894"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"18.512"}]}]}]},{"type":"SECONDARY","title":"Baseline Concentration of Tetrahydrobiopterin (BH4)(C0)","description":"Baseline concentration of BH4(C0) with associated inter-individual variability.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Absorption Rate Constant (Ka) of Kuvan","description":"Population pharmacokinetic parameter, Absorption Rate Constant (Ka)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.235","spread":"23.8"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (V/F) of Kuvan","description":"Population pharmacokinetic parameter apparent volume of distribution (V/F)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1209","spread":"56.4"}]}]}]},{"type":"SECONDARY","title":"Apparent Clearance (CL/F) of Kuvan","description":"Population pharmacokinetic parameter apparent clearance (CL/F)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"815","spread":"50.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":95},"commonTop":["Pyrexia","Upper respiratory tract infection","Vomiting","Cough","Nasopharyngitis"]}}}